[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"esophageal-achalasia\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:esophageal-achalasia":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,9,0,[8,51,88,111,135,162,186,212,241],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":4,"briefSummary":21,"conditions":22,"keywords":28,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":39,"lastUpdatePostDateStruct":40,"startDateStruct":43,"completionDateStruct":45,"leadSponsor":47,"locationsCount":50},"100077248","esophageal-cancer-risk-registry-100077248",false,"NCT00260585","Esophageal Cancer Risk Registry","Inclusion Criteria:\n\n* Known or suspected esophageal or gastroesophageal junction malignancy\n* Known Barrett's metaplasia\n* Clinical management of symptomatic gastroesophageal reflux disease (GERD)\n* Achalasia\n* Hiatal hernia\n\nExclusion Criteria:\n\n* Elevated pre-operative bloodwork will not have the additional biopsies taken.\n* Platelet count less than 150,000, partial thromboplastin time (PTT) of 50 or above, and\u002For International Normalized Ratio (INR) of 1.8 or above will not have the additional biopsies taken.","ALL","18 Years",{"count":18,"type":19},7000,"ESTIMATED","OBSERVATIONAL","The purpose of this study is to identify markers in the blood and tissue that could indicate risk factors for the development and progression of esophagus cancer. This research aims to collect medical history, blood, and tissue samples from patients who present with an esophageal disorder. Identifying genetic and behavioral risk factors involved in the development of esophageal cancer might allow for early detection and prevention. Survival and an opportunity for a cure with esophageal cancer will depend greatly on the stage of diagnosis. Tumors can develop changes in their genetic (hereditary) make-up, and these changes can sometimes be seen in normal tissues before the development of cancer. These genetic (hereditary) changes can serve as tumor markers and can be detected using methods that study changes in genetic material like DNA and RNA. The analysis of proteins can provide additional information. By identifying changes in these molecules that are different or altered in cancer, the investigators can use methods and tests for the detection of these changes.",[23,24,25,26,27],"Esophageal Cancer","Gastroesophageal Reflux Disease (GERD)","Esophageal Diseases","Hiatal Hernia","Esophageal Achalasia",[29,30,31,32,33,34,35,36,37],"gastroesophageal reflux disease","GERD","hiatal hernia","achalasia","Barrett's metaplasia","Anti-Reflux Surgery","Known\u002Fsuspected esophageal\u002Fgastroesophageal junction tumor","Esophageal disorders such as Barrett's metaplasia","Symptomatic gastroesophageal reflux disease","RECRUITING","2026-04-09",{"date":41,"type":42},"2026-04-14","ACTUAL",{"date":44,"type":42},"1999-06",{"date":46,"type":19},"2050-12",{"name":48,"class":49},"University of Pittsburgh","OTHER",1,{"id":52,"slug":53,"hasResults":11,"nctId":54,"briefTitle":55,"officialTitle":56,"acronym":57,"eligibilityCriteria":58,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":59,"targetDuration":4,"studyType":61,"phases":62,"briefSummary":65,"conditions":66,"keywords":72,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":79,"lastUpdatePostDateStruct":80,"startDateStruct":82,"completionDateStruct":84,"leadSponsor":86,"locationsCount":50},"100571535","phase-2-effectiveness-of-methods-for-pyloric-drainage-in-esophagectomy-botox-vs-pyloromyotomy-100571535","NCT06721520","Effectiveness of Methods for Pyloric Drainage in esophagecTomY: Botox vs. Pyloromyotomy","Comparative Effectiveness of Intrapyloric Botulinum Toxin Injection Versus Pyloromyotomy for Pyloric Drainage During Esophagectomy: A Registry-Based, Pragmatic Randomized Noninferiority Trial","EMPTY","Inclusion Criteria:\n\n* 18 years of age or older\n* Undergoing elective esophagectomy (thoracoabdominal, Ivor-Lewis, McKeown)\n* Receiving a gastric conduit for alimentary reconstruction\n* Technically able to receive either intrapyloric Botox injection or pyloromyotomy as ultimately determined intraoperatively\n* Willing and able to provide informed consent\n* Willing and able to participate in long-term follow up including study visits and surveys\n\nExclusion Criteria:\n\n* Undergoing emergent esophagectomy (e.g., for esophageal perforation)\n* Patients with underlying neuromuscular disease as Botox would be contraindicated (amyotrophic lateral sclerosis, myasthenia gravis, muscular dystrophies, Lambert-Eaton syndrome)\n* Patients undergoing left thoracoabdominal without left cervical neck incision (i.e., Sweet esophagectomy) - excluded due to the extent of gastric resection\n* Pregnancy\n* Allergy or hypersensitivity to botulinum toxin\n* Cannot feasibly receive both pyloric interventions as determined intraoperatively (e.g., patients with central obesity undergoing thoracoabdominal esophagectomy makes for a technically difficult pyloromyotomy)",{"count":60,"type":19},170,"INTERVENTIONAL",[63,64],"PHASE2","PHASE3","The goal of this pragmatic, registry-based, randomized clinical trial is to find out if using botulinum toxin (Botox) to help drain the stomach during an esophagectomy works as well as a pyloromyotomy in patients undergoing elective esophagectomy for benign or malignant esophageal disease. Both methods are intended to prevent problems with food emptying too slowly from the stomach (delayed gastric emptying), which can cause discomfort after surgery. The main question it aims to answer is:\n\nIs intrapyloric Botox injection as a drainage procedure during esophagectomy non-inferior in preventing symptoms of delayed gastric emptying at 6 months postoperatively compared to pyloromyotomy?\n\nResearchers will compare intrapyloric Botox injection to pyloromyotomy to see if Botox is non-inferior to pyloromyotomy in easing symptoms of delayed gastric emptying.\n\nParticipants will:\n\nBe randomized to one of two treatment groups-either intrapyloric Botox injection or pyloromyotomy-during their esophagectomy.\n\nComplete surveys assessing digestive symptoms at standard postoperative follow-up intervals (3 months, 6 months, 1 year, and 2 years postoperatively).\n\nUndergo a standard gastric emptying study at 6 months after surgery.",[67,68,69,25,27,70,71],"Esophageal Cancer Surgery","Esophagectomy","Delayed Gastric Emptying Following Procedure","Pylorus Dysfunction","Esophageal Dysmotility",[68,73,74,75,76,77,78],"Delayed gastric emptying","Delayed conduit emptying","Botox","botulinum toxin","Pyloromyotomy","Pyloric drainage","2026-02-23",{"date":81,"type":42},"2026-02-25",{"date":83,"type":42},"2024-12-03",{"date":85,"type":19},"2028-05-31",{"name":87,"class":49},"The Cleveland Clinic",{"id":89,"slug":90,"hasResults":11,"nctId":91,"briefTitle":92,"officialTitle":93,"acronym":4,"eligibilityCriteria":94,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":95,"targetDuration":4,"studyType":61,"phases":97,"briefSummary":98,"conditions":99,"keywords":4,"overallStatus":101,"whyStopped":4,"lastUpdateSubmitDate":102,"lastUpdatePostDateStruct":103,"startDateStruct":105,"completionDateStruct":107,"leadSponsor":109,"locationsCount":50},"100625695","phase-3-transverse-vs-longitudinal-mucosal-incision-during-poem-100625695","NCT07425977","Transverse vs Longitudinal Mucosal Incision During POEM","Transverse Versus Longitudinal Mucosal Incision in Peroral Endoscopic Myotomy: A Multicenter Randomized Clinical Trial","Inclusion Criteria:\n\n* Age ≥ 18 years\n* Diagnosis of achalasia or other spastic esophageal motility disorders with an indication for POEM\n* ASA physical status I-III\n* Ability to provide informed consent\n\nExclusion Criteria:\n\n* Prior myotomy or major esophageal surgery\n* Uncorrectable coagulopathy\n* Pregnancy\n* Active systemic infection\n* Contraindication to anesthesia\n* Any situation predicting technical inability to perform POEM",{"count":96,"type":19},140,[64],"Peroral endoscopic myotomy (POEM) is a minimally invasive endoscopic procedure used to treat achalasia and other spastic esophageal motility disorders. A key step in POEM is creating a small opening in the esophageal lining (mucosal incision) to enter the submucosal tunnel. This study evaluates whether making that entry incision \\*\\*transverse\\*\\* (across the esophagus) versus \\*\\*longitudinal\\*\\* (along the esophagus) improves procedural efficiency without reducing safety.\n\nThis is a \\*\\*multicenter, randomized (1:1), parallel-group clinical trial\\*\\* conducted in three therapeutic endoscopy units in Colombia (Hospital Universitario del Valle and Clínica Versalles in Cali, and Clínica del Occidente in Bogotá). Adults (≥18 years) with an indication for POEM, ASA I-III, and ability to provide informed consent will be eligible; key exclusions include prior myotomy\u002Fmajor esophageal surgery, uncorrectable coagulopathy, pregnancy, active systemic infection, anesthesia contraindication, or anticipated technical inability to perform POEM.\n\nAll procedures are standardized: POEM under \\*\\*general anesthesia with orotracheal intubation\\*\\*, \\*\\*CO₂ insufflation\\*\\*, validated endoscopic knives and preset electrosurgical modes; hemostasis with \\*\\*Coagrasper® only if needed\\*\\*; and closure using standard \\*\\*through-the-scope (TTS) clips\\*\\*. Participants are randomly assigned to a \\*\\*15 mm transverse mucosal incision\\*\\* (perpendicular to the esophageal axis) or a \\*\\*15 mm longitudinal mucosal incision\\*\\*. Full-procedure video is recorded for quality control and to allow objective timing, with blinded assessment of the primary outcome.\n\nThe \\*\\*primary outcome\\*\\* is the time (seconds) from the first mucosal cut to successful entry of the endoscope cap into the submucosal tunnel (advancing at least 1 cm). \\*\\*Secondary outcomes\\*\\* include need for hemostasis with Coagrasper®, number of clips required for complete closure, and early complications (including perforation and gas-related events such as capnoperitoneum requiring decompression and emphysema), monitored through \\*\\*30 days\\*\\*.\n\nParticipants complete a screening\u002Fpreoperative visit (up to 30 days before), undergo the POEM procedure, have early in-hospital\u002Fdischarge assessment (days 1-2), and receive safety follow-up contacts at approximately 1 week and day 30.\n\nRisks are those expected from standard POEM and peri-anesthesia care (e.g., bleeding, perforation, infection, and gas-related complications), and participants may not directly benefit clinically. However, the transverse incision may shorten access and closure time and reduce resource use without increasing short-term complications.\n\nThe study will be conducted with written informed consent, confidentiality protections (pseudonymization and secure storage), and reporting of results in aggregate form.",[27,100],"Spastic Esophageal Motility Disorders","NOT_YET_RECRUITING","2026-02-20",{"date":104,"type":42},"2026-02-24",{"date":106,"type":19},"2026-02-22",{"date":108,"type":19},"2026-08-02",{"name":110,"class":49},"Universidad Nacional de Colombia",{"id":112,"slug":113,"hasResults":11,"nctId":114,"briefTitle":115,"officialTitle":116,"acronym":117,"eligibilityCriteria":118,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":119,"targetDuration":4,"studyType":61,"phases":121,"briefSummary":123,"conditions":124,"keywords":4,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":125,"lastUpdatePostDateStruct":126,"startDateStruct":128,"completionDateStruct":130,"leadSponsor":132,"locationsCount":134},"100508393","routine-versus-symptomatic-protein-pump-inhibitor-therapy-for-prevention-of-gastroesophageal-reflux-after-per-oral-endoscopic-myotomy-for-esophageal-achalasia-100508393","NCT05899842","Routine Versus Symptomatic Protein Pump Inhibitor Therapy for Prevention of Gastroesophageal Reflux After Per Oral Endoscopic Myotomy for Esophageal Achalasia","Routine Versus Symptomatic Protein Pump Inhibitor Therapy for Prevention of Gastroesophageal Reflux After Per Oral Endoscopic Myotomy for Esophageal Achalasia. Randomized Open-label Clinical Trial","IPPOEM","Inclusion Criteria:\n\n* Patient with an indication for esophageal POEM for achalasia\n* Patient with all types of achalasia with Eckardt score \\> 3\n* The patient must have given their free and informed consent and signed the consent form\n* The patient must be a member or beneficiary of a health insurance plan\n\nExclusion Criteria:\n\n* Patient with contraindications to PPIs\n* Patient with mediastinal and esophageal neoplasia\n* Patient with a history of Heller myotomy surgery\n* Patients requiring any type of anti-reflux valve surgery\n* The subject is in a period of exclusion determined by a previous study\n* It is impossible to give the subject informed information\n* The patient is under safeguard of justice or state guardianship\n* Patient is pregnant, parturient or breastfeeding",{"count":120,"type":19},132,[122],"NA","Per Oral Endoscopic Myotomy (POEM) is a treatment of choice for achalasia with an excellent safety and efficacy profile. There is a high rate of esophagitis related to gastroesophageal reflux following this procedure. There is no recommendation on the prescription of protein pump inhibitors (PPI) after the procedure and no study has studied the benefit of systematic prescription of PPI after POEM for achalasia. The study authors hypothesize that routine PPI prescribing post-POEM for 12 months would reduce the rate of esophageal acid exposure compared to a symptom-based prescribing strategy.",[27],"2026-02-06",{"date":127,"type":42},"2026-02-10",{"date":129,"type":42},"2023-06-01",{"date":131,"type":19},"2028-02",{"name":133,"class":49},"Centre Hospitalier Universitaire de Nīmes",4,{"id":136,"slug":137,"hasResults":11,"nctId":138,"briefTitle":139,"officialTitle":140,"acronym":4,"eligibilityCriteria":141,"healthyVolunteers":11,"sex":15,"minAge":142,"maxAge":143,"enrollmentInfo":144,"targetDuration":4,"studyType":61,"phases":146,"briefSummary":147,"conditions":148,"keywords":149,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":153,"lastUpdatePostDateStruct":154,"startDateStruct":156,"completionDateStruct":158,"leadSponsor":160,"locationsCount":50},"100406926","assessment-of-different-modified-poem-for-achalasia-100406926","NCT04578769","Assessment of Different Modified POEM for Achalasia","Comparison Study of Conventional Peroral Endoscopic Myotomy (POEM) and Different Modified Procedures of POEM for Achalasia","Inclusion Criteria:\n\n* diagnosed as achalasia type I or II according to the Chicago Classification Version 4.0, with an Eckardt score \\>3\n* Their age is ≥14years and ≤70 years\n* Able to give written consent\n\nExclusion Criteria:\n\n* undergone previous surgical treatments\n* had contra-indication to general anesthesia\n* previous surgery of the mediastinum, stomach, or esophagus;\n* Pregnant or lactating female\n* type III achalasia\n* current alcohol or drug addiction, mental retardation, severe congenital or acquired coagulopathy (international normalized ratio \\>1.6)\n* hepatic cirrhosis with or without portal hypertension, eosinophilic esophagitis (biopsies were performed at index endoscopy), or confirmed Barrett's esophagus\n* esophageal diverticula or hiatal hernia based on findings from the index barium esophagram, or other conditions that the investigator believed not appropriate for POEM procedure","14 Years","70 Years",{"count":145,"type":19},52,[122],"The aims of this study is to compare the efficacy and safety of conventional myotomy (circular myotomy) and modified myotomy (full-thickness myotomy) in the treatment of achalasia patients.",[27],[150,151,152],"peroral endoscopic myotomy","Achalasia","thickness of myotomy","2025-12-03",{"date":155,"type":42},"2025-12-10",{"date":157,"type":42},"2020-09-02",{"date":159,"type":19},"2026-05-30",{"name":161,"class":49},"Peking Union Medical College Hospital",{"id":163,"slug":164,"hasResults":11,"nctId":165,"briefTitle":166,"officialTitle":166,"acronym":4,"eligibilityCriteria":167,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":168,"enrollmentInfo":169,"targetDuration":4,"studyType":20,"phases":4,"briefSummary":171,"conditions":172,"keywords":173,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":176,"lastUpdatePostDateStruct":177,"startDateStruct":179,"completionDateStruct":181,"leadSponsor":183,"locationsCount":50},"100547241","effects-of-malnutrition-on-respiratory-and-renal-functions-in-patients-undergoing-peroral-endoscopic-myotomy-poem-100547241","NCT06405412","Effects of Malnutrition on Respiratory and Renal Functions in Patients Undergoing Peroral Endoscopic Myotomy (POEM)","Inclusion Criteria:\n\n* Criteria for inclusion in the study:\n* Patients diagnosed with achalasia and suitable for POEM treatment by gastroenterology physicians\n* ASA 1-3\n* Between the ages of 18-80\n\nExclusion Criteria:\n\n* Criteria for exclusion from the study:\n* Those with a known history of active lung infection, advanced COPD, or respiratory failure\n* Patients with EF below 40%, severe ischemic heart failure, presence of valve disease\n* Those with bleeding diathesis and severe thrombocytopenia (limit 30-50 thousand)\n* severe kidney dysfunction\n* In the presence of known intolerance or allergy to certain medications for sedation, analgesia, or both\n* Pre-existing increased intracranial pressure\n* Having a BMI \\>30\n* Severe uncorrected hypovolemiaHistory of radiotherapy to the esophagus\n* History of mucosal resection or ablation in the area where POEM will be applied\n* Presence of cirrhosis and portal hypertension.","80 Years",{"count":170,"type":19},60,"The hypothesis of this study is to investigate cardiorespiratory and renal complications in patients under general anesthesia undergoing POEM surgery.",[27],[174,175,27],"Peroral Endoscopic Myotomy","anesthesia","2025-11-16",{"date":178,"type":42},"2025-11-19",{"date":180,"type":42},"2023-11-01",{"date":182,"type":19},"2026-07-30",{"name":184,"class":185},"Umraniye Education and Research Hospital","OTHER_GOV",{"id":187,"slug":188,"hasResults":11,"nctId":189,"briefTitle":190,"officialTitle":191,"acronym":192,"eligibilityCriteria":193,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":194,"targetDuration":4,"studyType":20,"phases":4,"briefSummary":196,"conditions":197,"keywords":198,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":203,"lastUpdatePostDateStruct":204,"startDateStruct":206,"completionDateStruct":208,"leadSponsor":210,"locationsCount":50},"100533801","marimpach--contribution-of-high-resolution-manometry-with-impedancemetry-for-the-evaluation-of-esophageal-clearance-in-achalasia-100533801","NCT06230536","MARIMPACH : Contribution of High-resolution Manometry With Impedancemetry for the Evaluation of Esophageal Clearance in Achalasia","Contribution of High-resolution Manometry With Impedancemetry for the Evaluation of Esophageal Clearance in Achalasia","MARIMPACH","Inclusion Criteria:\n\n* The patients included are all patients treated by POEM at Bordeaux University Hospital between October 2020 and September 2024.\n\nExclusion Criteria:\n\n* Primary POEM failure, lost to follow-up, absence of completion of the ES, TBE or HRiM pre or post poem at 3 months.",{"count":195,"type":19},104,"Outcome after treatment of achalasia is usually assessed by the Eckardt score (ES). The timed barium esophagogram (TBE) is used to objectively assess esophageal clearance after treatment. High-resolution manometry with impedancemetry (HRiM) provides information on esophageal clearance of liquids in addition to motility parameters. The aim of this study was to compare esophageal clearance determined by HRiM and TBE in patients with achalasia treated by POEM.",[27],[199,200,201,202],"timed baryum esophagogram","high-resolution manometry with impedancemetry","esophageal clearance","Eckardt score","2024-07-25",{"date":205,"type":42},"2024-07-26",{"date":207,"type":42},"2024-02-01",{"date":209,"type":19},"2028-12-01",{"name":211,"class":49},"University Hospital, Bordeaux",{"id":213,"slug":214,"hasResults":11,"nctId":215,"briefTitle":216,"officialTitle":217,"acronym":4,"eligibilityCriteria":218,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":219,"enrollmentInfo":220,"targetDuration":4,"studyType":61,"phases":222,"briefSummary":223,"conditions":224,"keywords":228,"overallStatus":101,"whyStopped":4,"lastUpdateSubmitDate":232,"lastUpdatePostDateStruct":233,"startDateStruct":235,"completionDateStruct":237,"leadSponsor":239,"locationsCount":50},"100518180","randomized-controlled-study-of-optical-3d-navigated-repetitive-transcranial-magnetic-stimulation-for-achalasia-100518180","NCT06027190","Randomized Controlled Study of Optical 3D Navigated Repetitive Transcranial Magnetic Stimulation for Achalasia.","To Investigate the Clinical Efficacy of Optical 3D Navigation Repetitive Transcranial Magnetic Stimulation (rTMS) in the Treatment of Achalasia, Optimize the Treatment Parameters, and Provide a Noninvasive Treatment Strategy for Achalasia","Inclusion Criteria:\n\n* Aged more than 18 years old, less than 75 years old;\n* Clinical symptoms evaluation, HREM, esophageal barium meal examination confirmed the diagnosis of achalasia;\n* Willing to sign informed consent.\n\nExclusion Criteria:\n\n* Presence of metal hardware in close contact with the discharge coil (e.g., cochlear implant, internal pulse generator, or drug pump). Note: Cochlear implants include electrodes, magnets, loop antennas, and electronic chips under the scalp implanted in the cochlea;\n* Intracranial metal implants;\n* Patients with cardiac pacemakers, vagal nerve stimulation (VNS) systems, spinal cord stimulators, and deep brain stimulation implanted with pulse generators should be used with caution;\n* People at higher risk of noisy hearing loss and patients with hypoacusis symptoms should be used with caution;\n* Pregnancy;\n* Severe or recent heart disease;\n* Personal history of epilepsy, use of known drugs that lower the seizure threshold, and other factors that may lower the seizure threshold (e.g., lack of sleep, infection, and alcohol abuse);\n* Increased intracranial pressure;\n* Acute phase of intracranial infection and hemorrhagic disease;\n* Contraindications to MRI examination or claustrophobia;\n* Refusal to sign informed consent.","75 Years",{"count":221,"type":19},112,[122],"The goal of this clinical trial is to investigate the clinical efficacy of repetitive transcranial magnetic stimulation in the treatment of achalasia in patients diagnosed with achalasia by comprehensive evaluation of clinical symptoms, HREM, and barium meal examination, optimize rTMS treatment parameters, and provide an effective and noninvasive new treatment strategy for achalasia. The main questions it aims to answer are:\n\n1. To investigate the clinical efficacy of individualized treatment of achalasia with optical 3D navigation repetitive transcranial magnetic stimulation.\n2. Optimize rTMS parameters to achieve the best clinical treatment.\n\nParticipants will need to fill out the Eckardt score scale and SF-36 quality of life scale, undergo cranial T1 structural magnetic resonance for functional connectivity analysis, and select the brain region with the strongest positive functional connectivity to the DMV as the rTMS target. All patients were randomly divided into four groups: sham-rTMS group, 5Hz-rTMS group, 10Hz-rTMS group, and 30Hz-rTMS group, and each group received acute and chronic stimulation, respectively. In the acute stimulation stage, patients only need to do rTMS once, and HREM and HRV detection are given before and after rTMS (stimulation for 1s, interval for 4s, 10 pulses per second, receiving a total of 3000 pulses); in the chronic stimulation stage, patients receive 25 minutes of rTMS actual stimulation or sham stimulation each time, lasting for 20 times, which is completed within 30 days, and the actual stimulation parameters are the same as those of acute stimulation, and the sham stimulation coil is consistent with the appearance and sound of proper stimulation, but there is no substantial stimulation. High-definition esophageal manometry, timed barium meal, heart rate coefficient of variation, and serum neurotransmitters were performed before and after chronic stimulation. Finally, a weekly telephone follow-up was performed for 12 weeks, including Eckardt score and SF-36 quality of life scale.",[27,225,226,227],"Transcranial Magnetic Stimulation, Repetitive","Vagus Nerve Motor Disorder","Functional Magnetic Resonance Imaging",[151,229,230,231],"rTMS","fMRI","Non-invasive","2023-09-15",{"date":234,"type":42},"2023-09-21",{"date":236,"type":19},"2024-01-01",{"date":238,"type":19},"2026-12-31",{"name":240,"class":49},"Zhang Nina",{"id":242,"slug":243,"hasResults":11,"nctId":244,"briefTitle":245,"officialTitle":246,"acronym":247,"eligibilityCriteria":248,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":249,"targetDuration":4,"studyType":61,"phases":251,"briefSummary":252,"conditions":253,"keywords":4,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":254,"lastUpdatePostDateStruct":255,"startDateStruct":257,"completionDateStruct":259,"leadSponsor":261,"locationsCount":50},"100248889","per-oral-endoscopic-myotomy-poem-and-prolonged-dilatation-prd-for-achalasia-100248889","NCT02518542","Per Oral Endoscopic Myotomy (POEM) and Prolonged Dilatation (PRD) for Achalasia","Per Oral Endoscopic Myotomy (POEM) and Prolonged Dilatation (PRD) as Additional Endoscopic Treatment Options for Achalasia and Other Esophageal Motility Disorders","POETA","Inclusion Criteria:\n\n* Confirmed diagnosis of achalsia, hypertensive lower esophageal sphincter, nutcracker esophagus, or diffuse esophageal spasm\n\nExclusion Criteria:\n\n* Contraindication for EGD",{"count":250,"type":19},400,[122],"Achalasia is an esophageal motility disorder, which leads to clinical symptoms such as dysphagia, regurgitation, chest pain and consecutive weight loss.\n\nAlthough conventional treatment such as laparoscopic Heller myotomy (LHM) and balloon dilatation (BD) can provide sufficient symptom relief in many patients, both interventions have their individual drawbacks. Additionally, treatment after failed LHM or BD can be challenging and in few might even lead to esophagectomy.\n\nPer oral endoscopic myotomy (POEM) and prolonged dilatation (PRD) are two novel endoscopically performed therapeutic options for achalasia and other esophageal motility disorders. Both not only appear to provide good results, when performed as initial treatment but also might be an excellent option after e.g failed LHM.\n\nThe purpose of this study is to evaluate the long-term efficacy of four different treatment options, such as POEM, PRD with stent-fixation, PD and conventional LHM for achalasia in an individualized treatment setting.",[27],"2015-08-07",{"date":256,"type":19},"2015-08-10",{"date":258,"type":4},"2014-06",{"date":260,"type":19},"2027-06",{"name":262,"class":49},"Medical University of Vienna"]